Appendix 1- Molnupiravir

Treatment Information

Molnupiravir is an oral (i.e. taken by mouth) antiviral treatment that was initially developed for treatment of influenza. The treatment has been shown to have a good safety profile. In a number of clinical trials it has been shown to improve recovery from COVID-19 symptoms and reduce the need to be admitted to hospital, and may therefore be an effective treatment for COVID-19.

Molnupiravir has a conditional license, which means that it has been licensed for use as a treatment based on less data than normally required. To receive this license, the data has shown that the treatment's benefits outweigh the risks. The aim of PANORAMIC is to collect more data to confirm whether Molnupiravir is an effective COVD-19 treatment.

Molnupiravir Dose and Administration

Molnupiravir is a new possible treatment for COVID-19, so the most effective dose is unknown. Studies like this are trying to find out how well the treatment works.

For this trial, 4 capsules (200 mg) of Molnupiravir are to be taken orally twice a day for 5 days.

If you decide that you no longer wish to take the medication, you will be asked to return your medication to the trial team in the pre-paid envelope.

Potential COVID-19 Treatment

Several small clinical studies have found that Molnupiravir may help to treat COVID-19. However, we need more evidence from large clinical trials, which is why we have included the treatment in the PANORAMIC Trial. Molnupiravir has been highly recommended by the Antivirals Taskforce (ATF) for the treatment of COVID-19.

The use of molnupiravir in PANORAMIC has been approved by the MHRA. The MHRA regulates the use of all medicines in the UK.

Exclusion Criteria

Before you are enrolled, you will be asked if you meet any of the following reasons for NOT taking

Molnupiravir. If you meet ANY of the following criteria, you will automatically be excluded from receiving Molnupiravir.

Exclusions: If you meet any of the following criteria you should not take Molnupiravir

- Patients currently admitted to hospital (inpatient)
- Previously enrolled in the PANORAMIC trial
- Currently participating in a clinical trial which involves taking a new medication for COVID-19
- Known or suspected pregnancy (confirmed by a negative pregnancy test)
- Breastfeeding
- Participants of childbearing potential or participants who are a partner to someone of childbearing potential and in a heterosexual relationship, who are NOT willing to use highly effective contraceptive for a period of 28 days duration of the trial.
- Known allergy to Molnupiravir
- Currently taking Molnupiravir outside the trial.

A registered nurse or doctor will telephone you to discuss these screening questions with you and to check that you can take the treatment. Once confirmed you will be enrolled into the trial.

Participants of childbearing potential must agree to perform a pregnancy test provided by the trial, and confirm a negative test result before taking Molnupiravir. This negative test result is required regardless of their current contraception methods or relationship status.

Contraception

As there is currently no human research associated with the use of Molnupiravir among pregnant or lactating people, it is important that participants of childbearing potential, or with a partner of childbearing potential, and in a heterosexual relationship, must use highly effective contraceptives from enrolment until day 28 of follow-up. Participants of child-bearing age will also be required to confirm a negative pregnancy test (test provided by the trial), prior to starting the medication.

Methods of contraception that are acceptable for the trial include the following:

The implant, the coil and male or female sterilisation will be acceptable for the trial. The injection and most forms of hormonal contraception will also be deemed acceptable for the trial if used in combination with condoms or other barrier methods. However, condoms alone won't be sufficient during the trial. You can discuss any questions you have about contraception during the trial period

with the trial team. **If you were to become pregnant during the trial you must tell us immediately and you will be withdrawn from the trial, although we will ask to follow you up for safety reasons.**

It is important to note that a barrier method on its own is not sufficient

Side-effects

Common side effects include dizziness, headache, diarrhoea and nausea.

A trial doctor or research nurse will call you the day after you start your medication (Day 2) to ask about these and any other side-effects you may have experienced. If you experience any side-effects which you're concerned about while taking Molnupiravir, you will be given access to a 24-hour telephone line to speak to a member of the clinical team. Any symptoms reported in your daily diary are monitored by our clinical team who will call you if there any symptoms of concern.

Emergencies

If a medical emergency related to your treatment for this trial occurs while you are at home, you should initially try to contact the usual services that are open to you, such as 111, 999 or go to the accident and emergency (A&E) department at your local hospital. If you are unable to get to the hospital you should contact your GP who, with your consent, will already have been informed of your participation in the trial. You have been given a PANORAMIC participant card that you must show to the Doctor you see.